All Relations between Alzheimer Disease and microtubule-associated protein tau

Publication Sentence Publish Date Extraction Date Species
Ignacio Mateo, Pascual Sánchez-Juan, Eloy Rodríguez-Rodríguez, Jon Infante, Carlos Fernández-Viadero, Nicolás Peña, José Berciano, Onofre Combarro. 14-3-3 zeta and tau genes interactively decrease Alzheimer's disease risk. Dementia and geriatric cognitive disorders. vol 25. issue 4. 2008-06-17. PMID:18319590. abnormal tau hyperphosphorylation has been suggested as being one of the central events in the development of neurofibrillary tangles, which are one of the characteristic neuropathological lesions found in alzheimer's disease (ad) brains. 2008-06-17 2023-08-12 human
Jie Zhou, Juan Chen, Youmei Fen. Effect of truncated-ApoE4 overexpression on tau phosphorylation in cultured N2a cells. Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban. vol 26. issue 3. 2008-06-16. PMID:16961266. it was concluded that in vitro overexpression of truncated-apoe4 (delta272-299) can result in tau hyperphosphorylation in n2a cells by activating gsk-3, suggesting truncated-apoe4 (delta272-299) might contribute the pathogenesis of alzheimer disease. 2008-06-16 2023-08-12 Not clear
Z Wei, M S Song, D MacTavish, J H Jhamandas, S Ka. Role of calpain and caspase in beta-amyloid-induced cell death in rat primary septal cultured neurons. Neuropharmacology. vol 54. issue 4. 2008-06-12. PMID:18222494. the invariant characteristic features associated with alzheimer's disease (ad) brain include the presence of extracellular neuritic plaques composed of amyloid beta (abeta) peptide, intracellular neurofibrillary tangles containing hyper-phosphorylated tau protein and the loss of basal forebrain cholinergic neurons. 2008-06-12 2023-08-12 rat
John C Steele, Patrick L McGee. The ALS/PDC syndrome of Guam and the cycad hypothesis. Neurology. vol 70. issue 21. 2008-06-12. PMID:18490618. this includes induction of neurofibrillary tangles with a tau isoform distribution similar to that of alzheimer disease and association of the lesions with tdp-43 and lrrk2. 2008-06-12 2023-08-12 Not clear
Leslie M Kleva. Alzheimer's disease as copper deficiency. Medical hypotheses. vol 70. issue 4. 2008-06-10. PMID:17928161. decreased cognition and increased tau in cerebrospinal fluid in alzheimer's disease also are associated with low copper status. 2008-06-10 2023-08-12 Not clear
She Chen, Bin Li, Inge Grundke-Iqbal, Khalid Iqba. I1PP2A affects tau phosphorylation via association with the catalytic subunit of protein phosphatase 2A. The Journal of biological chemistry. vol 283. issue 16. 2008-06-10. PMID:18245083. in alzheimer disease (ad) brain, the level of i (1)(pp2a), a 249-amino acid long endogenous inhibitor of protein phosphatase 2a (pp2a), is increased, the activity of the phosphatase is decreased, and the microtubule-associated protein tau is abnormally hyperphosphorylated. 2008-06-10 2023-08-12 Not clear
Tadanori Hamano, Tania F Gendron, Ena Causevic, Shu-Hui Yen, Wen-Lang Lin, Ciro Isidoro, Michael Deture, Li-wen K. Autophagic-lysosomal perturbation enhances tau aggregation in transfectants with induced wild-type tau expression. The European journal of neuroscience. vol 27. issue 5. 2008-06-03. PMID:18294209. the intracellular assembly of tau aggregates is a pathological hallmark shared by alzheimer's disease and other neurodegenerative disorders known collectively as tauopathies. 2008-06-03 2023-08-12 human
Kayoko Okuyama, Chisato Nishiura, Fumie Mizushima, Katsuhiko Minoura, Miho Sumida, Taizo Taniguchi, Koji Tomoo, Toshimasa Ishid. Linkage-dependent contribution of repeat peptides to self-aggregation of three- or four-repeat microtubule-binding domains in tau protein. The FEBS journal. vol 275. issue 7. 2008-06-03. PMID:18312411. although one of the priorities in alzheimer's research is to clarify the filament formation mechanism for the tau protein, it is still unclear how it is transformed from a normal structure in a neuron. 2008-06-03 2023-08-12 Not clear
Tamar Amit, Yael Avramovich-Tirosh, Moussa B H Youdim, Silvia Mande. Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. vol 22. issue 5. 2008-05-28. PMID:18048580. dysregulation of brain iron homeostasis is central to early neuropathological events in alzheimer's disease (ad), including oxidative stress, inflammatory processes, amyloid deposition, tau phosphorylation, and neuronal cell cycle regulatory failure, leading to apoptosis. 2008-05-28 2023-08-12 Not clear
Martyna Songin, Henryk Jeśko, Grzegorz Czapski, Agata Adamczyk, Robert P Strosznajde. GSK-3beta and oxidative stress in aged brain. Role of poly(ADP- -ribose) polymerase-1. Folia neuropathologica. vol 45. issue 4. 2008-05-20. PMID:18176896. in alzheimer's disease it is responsible for hyperphosphorylation of tau. 2008-05-20 2023-08-12 rat
Mirko Bibl, Brit Mollenhauer, Hermann Esselmann, Michael Schneider, Piotr Lewczuk, Volker Welge, Martin Gross, Peter Falkai, Johannes Kornhuber, Jens Wiltfan. Cerebrospinal fluid neurochemical phenotypes in vascular dementias: original data and mini-review. Dementia and geriatric cognitive disorders. vol 25. issue 3. 2008-05-20. PMID:18270488. the study evaluated the patterns of cerebrospinal fluid (csf), amyloid-beta (abeta) peptides, total tau and phospho-tau among alzheimer's disease (ad) and vascular dementias (vad). 2008-05-20 2023-08-12 Not clear
T Engel, P Goñi-Oliver, E Gómez de Barreda, J J Lucas, F Hernández, J Avil. Lithium, a potential protective drug in Alzheimer's disease. Neuro-degenerative diseases. vol 5. issue 3-4. 2008-05-15. PMID:18322403. since a main tau kinase is glycogen synthase kinase 3 (gsk-3), the use of specific gsk-3 inhibitors, like lithium, could be a potential therapy in alzheimer's disease. 2008-05-15 2023-08-12 Not clear
T Engel, P Goñi-Oliver, E Gómez de Barreda, J J Lucas, F Hernández, J Avil. Lithium, a potential protective drug in Alzheimer's disease. Neuro-degenerative diseases. vol 5. issue 3-4. 2008-05-15. PMID:18322403. in this short article, we have done a review on tau phosphorylation in alzheimer's disease and other tauopathies, and on the inhibition of kinases like gsk-3, involved in tau modification. 2008-05-15 2023-08-12 Not clear
Pierrot Nathalie, Octave Jean-Noë. Processing of amyloid precursor protein and amyloid peptide neurotoxicity. Current Alzheimer research. vol 5. issue 2. 2008-05-15. PMID:18393795. biochemical analysis of these two proteins in primary cultures of neurons show that phosphorylation of both app and tau can be a factor linking the two characteristic lesions of alzheimer's disease. 2008-05-15 2023-08-12 human
Bruce A Yankner, Tao Lu, Patrick Loerc. The aging brain. Annual review of pathology. vol 3. 2008-05-13. PMID:18039130. toxic protein aggregates have been identified as potential contributory factors, including amyloid beta-protein in alzheimer's disease, tau in frontotemporal dementia, and alpha-synuclein in parkinson's disease. 2008-05-13 2023-08-12 Not clear
Dick Terwel, David Muyllaert, Ilse Dewachter, Peter Borghgraef, Sophie Croes, Herman Devijver, Fred Van Leuve. Amyloid activates GSK-3beta to aggravate neuronal tauopathy in bigenic mice. The American journal of pathology. vol 172. issue 3. 2008-05-09. PMID:18258852. the hypothesis that amyloid pathology precedes and induces the tau pathology of alzheimer's disease is experimentally supported here through the identification of gsk-3 isozymes as a major link in the signaling pathway from amyloid to tau pathology. 2008-05-09 2023-08-12 mouse
Peter Wostyn, Kurt Audenaert, Peter Paul De Dey. Alzheimer's disease-related changes in diseases characterized by elevation of intracranial or intraocular pressure. Clinical neurology and neurosurgery. vol 110. issue 2. 2008-05-07. PMID:18061341. with regard to normal pressure hydrocephalus, evidence suggests that changes in cerebrospinal fluid circulatory dynamics ultimately may result in reduced clearance of neurotoxins, such as beta-amyloid peptides and tau protein, that play a role in the pathogenesis of alzheimer's disease. 2008-05-07 2023-08-12 Not clear
S G Lindquist, I E Holm, M Schwartz, I Law, J Stokholm, M Batbayli, G Waldemar, J E Nielse. Alzheimer disease-like clinical phenotype in a family with FTDP-17 caused by a MAPT R406W mutation. European journal of neurology. vol 15. issue 4. 2008-05-07. PMID:18284428. we report clinical, molecular, neuroimaging and neuropathological features of a danish family with autosomal dominant inherited dementia, a clinical phenotype resembling alzheimer's disease and a pathogenic mutation (r406w) in the microtubule associated protein tau (mapt) gene. 2008-05-07 2023-08-12 Not clear
Asgar Zaheer, Scott Knight, Ashna Zaheer, Marcus Ahrens, Shailendra K Sahu, Baoli Yan. Glia maturation factor overexpression in neuroblastoma cells activates glycogen synthase kinase-3beta and caspase-3. Brain research. vol 1190. 2008-05-06. PMID:18054898. taken together our results imply that gmf is involved in the signaling leading to the activation of gsk-3beta and caspase-3 in n18 cells and strongly suggest its involvement in neurodegeneration since gsk-3beta is known to hyperphosphorylate tau which is associated with the neurotoxicity of neurofibrillary tangles in alzheimer's disease. 2008-05-06 2023-08-12 Not clear
Theresa J Kannanayakal, Jerry R Mendell, Jeff Kure. Casein kinase 1 alpha associates with the tau-bearing lesions of inclusion body myositis. Neuroscience letters. vol 431. issue 2. 2008-05-02. PMID:18191026. inclusion body myositis and alzheimer's disease are age-related disorders characterized in part by the appearance of intracellular lesions composed of filamentous aggregates of the microtubule-associated protein tau. 2008-05-02 2023-08-12 Not clear